Opioid Reduction Outcomes, Sensitivity Sample Excluding Complete Discontinuation Patients with No Further Clinic Visit Following Last Opioid Prescription
| Average daily dose at baseline | |||||
|---|---|---|---|---|---|
| Total N = 1,465 n (column %) | <20 MME N = 634 column % | 20 to < 50 MME N = 473 column % | 50 to <90 MME N = 200 column % | ≥90 MME N = 158 column % | |
| Opioid reduction measures at end of follow-up | |||||
| Reduced to 0 MME | 565 (38.6%) | 44.3% | 35.7% | 33.0% | 31.0% |
| Mean (SD) number of calendar quarters to reduce to zero MME | 3.0 (1.7) | 2.7 (1.6) | 3.1 (1.7) | 3.6 (1.7) | 3.9 (1.6) |
| Partially reduced MME | 536 (36.6%) | 28.2% | 38.1% | 40.5% | 60.8% |
| Mean (SD) MME at end of follow-up, among patients with partial reduction | 28.0 (33.5) | 7.4 (4.5) | 18.9 (10.1) | 36.3 (18.9) | 76.4 (49.1) |
| Did not reduce MME | 364 (24.9%) | 27.4% | 26.2% | 26.5% | 8.2% |
| Average daily dose at end of follow-up | |||||
| 0 MME | 565 (38.6%) | 44.3% | 35.7% | 33.0% | 31.0% |
| 1 to <20 MME | 415 (28.3%) | 46.4% | 19.7% | 10.0% | 5.1% |
| 20 to <50 MME | 287 (19.6%) | 7.7% | 38.1% | 18.0% | 13.9% |
| 50 to <90 MME | 133 (9.1%) | 1.3% | 6.1% | 30.5% | 22.2% |
| ≥90 MME | 65 (4.4%) | <1% | <1% | 8.5% | 27.9% |
Abbreviation: MME, morphine milligram equivalence.
Patient Ns have been suppressed in this table due to some small cell sizes.